Bod Australia (ASX:BDA) - CEO, Jo Patterson
CEO, Jo Patterson
Source: InvestorStream
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Bod Australia (BDA) has recorded its highest-ever month of medicinal cannabis sales, filling 1789 MediCabilis prescriptions in April
  • This marks an 11 per cent increase from the 1617 prescriptions in March and brings the total MediCabilis orders filled in FY21 to 9519
  • Of the orders filled in April, 64 per cent of the prescriptions were repeat orders
  • This growth is based on the ongoing engagement and strong relationships with prescribers, physicians and healthcare professionals
  • Bod is up a healthy 18.9 per cent on the market and shares are trading at 44 cents

Bod Australia (BDA) has recorded its highest-ever month of medicinal cannabis sales, filling 1789 MediCabilis prescriptions in April.

This marks an 11 per cent increase from the 1617 prescriptions in March and brings the total MediCabilis orders filled in FY21 to 9519.

Of the orders filled in April, 64 per cent of the prescriptions were repeat orders.

This growth is based on the ongoing engagement and strong relationships with prescribers, physicians and healthcare professionals.

Since prescriptions first began in 2019, 13,624 MediCabilis units have been sold.

“MediCabilis volumes continue to grow at a very pleasing rate and the recent prescription sales growth further highlight’s Bod’s ability to generate strong revenues across one of the company’s two core operating divisions,” CEO Jo Patterson commented.

“The company continues to maintain a solid segment of the total Australian market through Special Access Scheme Category B,” she said.

“The company has a number of new products in the pipeline that will be launched imminently. We anticipate that the introduction of new products and scale up of operations across both business divisions will unlock considerable value for shareholders,” she added.

Bod is up a healthy 18.9 per cent on the market and shares are trading at 44 cents at 1:50 pm AEST.

BDA by the numbers
More From The Market Herald
Argenica Therapeutics (ASX:AGN) - CEO, Dr Liz Dallimore

" Argenica Therapeutics (ASX:AGN) determines safe starting dose level for ARG-007

Argenica Therapeutics (ASX:AGN) determines safe starting dose level from toxicology and genotoxicity studies
Arovella Therapeutics (ASX:ALA) - CEO and Managing Director, Dr Michael Baker

" Arovella Therapeutics (ASX:ALA) to raise $6m for cell therapies

Arovella Therapeutics (ASX:ALA) has received firm commitments from institutional and sophisticated investors for a $4.57 million…

" Radiopharm Theranostics (ASX:RAD) acquires IP ownership of Radiopharmaceutical Nanobodies

Radiopharm Theranostics (ASX:RAD) acquires full intellectual property (IP) ownership to three assets from NanoMab Technology.
Nuheara (ASX:NUH) - CEO, Justin Miller

" Nuheara (ASX:NUH) completes $1.06m SPP

Hearing technology company Nuheara (ASX:NUH) has completed its share purchase plan (SPP) with applications totalling $1,067,200.